WO2006095029A3 - Conjugues di-polymere-proteine et procedes de preparation de ceux-ci - Google Patents

Conjugues di-polymere-proteine et procedes de preparation de ceux-ci Download PDF

Info

Publication number
WO2006095029A3
WO2006095029A3 PCT/EP2006/060671 EP2006060671W WO2006095029A3 WO 2006095029 A3 WO2006095029 A3 WO 2006095029A3 EP 2006060671 W EP2006060671 W EP 2006060671W WO 2006095029 A3 WO2006095029 A3 WO 2006095029A3
Authority
WO
WIPO (PCT)
Prior art keywords
processes
preparation
protein conjugates
polymer protein
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/060671
Other languages
English (en)
Other versions
WO2006095029A2 (fr
Inventor
Michael Bavand
Horst Blasey
Dietmar Lang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siegfried AG
Original Assignee
Siegfried AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siegfried AG filed Critical Siegfried AG
Priority to EP06725029A priority Critical patent/EP1869079A2/fr
Priority to JP2008500216A priority patent/JP2008535793A/ja
Publication of WO2006095029A2 publication Critical patent/WO2006095029A2/fr
Publication of WO2006095029A3 publication Critical patent/WO2006095029A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention porte sur des conjugués protéine-di-polymère et sur des procédés de préparation de ceux-ci. Cette invention porte également sur l'utilisation d'un tel conjugué di-polymère-protéine, en particulier d'un conjugué de protéine di-pégylée, pour fabriquer un médicament servant au traitement de troubles.
PCT/EP2006/060671 2005-03-11 2006-03-13 Conjugues di-polymere-proteine et procedes de preparation de ceux-ci Ceased WO2006095029A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP06725029A EP1869079A2 (fr) 2005-03-11 2006-03-13 Conjugues di-polymere-proteine et procedes de preparation de ceux-ci
JP2008500216A JP2008535793A (ja) 2005-03-11 2006-03-13 ジポリマー・タンパク質コンジュゲートおよびその調製方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP2005/002632 2005-03-11
PCT/EP2005/002632 WO2006094530A1 (fr) 2005-03-11 2005-03-11 Conjugues de proteines et de dipolymeres et leurs procedes de preparation

Publications (2)

Publication Number Publication Date
WO2006095029A2 WO2006095029A2 (fr) 2006-09-14
WO2006095029A3 true WO2006095029A3 (fr) 2006-11-30

Family

ID=35276216

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2005/002632 Ceased WO2006094530A1 (fr) 2005-03-11 2005-03-11 Conjugues de proteines et de dipolymeres et leurs procedes de preparation
PCT/EP2006/060671 Ceased WO2006095029A2 (fr) 2005-03-11 2006-03-13 Conjugues di-polymere-proteine et procedes de preparation de ceux-ci

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/002632 Ceased WO2006094530A1 (fr) 2005-03-11 2005-03-11 Conjugues de proteines et de dipolymeres et leurs procedes de preparation

Country Status (2)

Country Link
JP (1) JP2008535793A (fr)
WO (2) WO2006094530A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11559567B2 (en) 2014-11-06 2023-01-24 Pharmaessentia Corporation Dosage regimen for pegylated interferon

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7052686B2 (en) 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
EP1834963A1 (fr) * 2006-03-13 2007-09-19 Siegfried Ltd. Conjugues de proteines et de dipolymeres et leurs procedes de preparation
CA2664304C (fr) 2006-09-28 2017-08-22 Schering Corporation Utilisation d'il-10 pegilee pour traiter un cancer
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
CN101627056B (zh) * 2007-12-29 2013-05-15 厦门伯赛基因转录技术有限公司 Y型聚乙二醇修饰的g-csf及其制备方法和应用
CN101981057B (zh) 2008-03-31 2013-07-24 旭化成纤维株式会社 纤维素衍生物微粒、该微粒的分散液、该微粒的分散体及诊断药
US9840546B2 (en) * 2008-04-03 2017-12-12 Biosteed Gene Expression Tech. Co., Ltd. Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
HRP20161040T1 (hr) * 2008-04-29 2016-12-16 Ascendis Pharma Growth Disorders Division A/S Pegilirani rekombinantni spojevi ljudskog hormona rasta
MY156568A (en) * 2008-07-31 2016-03-15 Pharmaessentia Corp Peptide-polymer conjugates
CA2742064A1 (fr) * 2008-10-31 2010-05-06 Amgen Inc. Materiels et procedes associes a la mobilisation de cellules souches par le facteur de croissance hematopoietique g-csf polypegyle
EP3348281B1 (fr) * 2008-12-17 2023-07-05 Merck Sharp & Dohme Corp. Production d'il-10 mono- et di-pégylé et ses utilisations
EP2986306A4 (fr) 2013-04-18 2016-12-07 Armo Biosciences Inc Méthodes d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
ES2688206T3 (es) 2013-06-17 2018-10-31 Armo Biosciences, Inc. Procedimiento de evaluación de la identidad y la estabilidad de proteínas
EP3068425B1 (fr) 2013-11-11 2021-01-27 Armo Biosciences, Inc. Méthodes d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
WO2015187295A2 (fr) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Méthodes permettant de faire baisser le cholestérol sérique
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
CA2986755A1 (fr) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Interleukine 10 pegylee utilisee pour le traitement du cancer
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers
CN110702895B (zh) * 2018-12-28 2024-03-01 上海长岛生物技术有限公司 D-二聚体检测试剂和方法、试剂制备方法及聚乙二醇应用
CN113926001B (zh) * 2021-09-13 2023-03-07 熹微(苏州)生物医药科技有限公司 一种仿生角膜及其制备方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011953A1 (fr) * 1994-10-12 1996-04-25 Amgen Inc. Compositions de proteines ayant subi une modification chimique a l'extremite n-terminale et procedes
WO1998025965A2 (fr) * 1996-12-11 1998-06-18 Glaxo Group Limited Peptides et composes qui se lient a un recepteur
WO2000021574A2 (fr) * 1998-10-14 2000-04-20 Amgen Inc. Double polyethyleneglycolation de proteines dirigee sur site pour augmenter la bioactivite et la biocompatibilite
WO2001051510A2 (fr) * 2000-01-10 2001-07-19 Maxygen Holdings Ltd Produits conjugues g-csf
WO2001076640A2 (fr) * 2000-04-07 2001-10-18 Amgen Inc. Nouvelles compositions chimiquement modifiees de proteines stimulant erythropoietine et procedes
US20030143596A1 (en) * 2001-11-07 2003-07-31 Shearwater Corporation Branched polymers and their conjugates
WO2004028568A1 (fr) * 2002-09-27 2004-04-08 F. Hoffmann-La Roche Ag Conjugues de proteine de liaison du facteur de croissance insulinomimetique 4 et de poly (ethylene glycol)
WO2004083242A1 (fr) * 2003-03-21 2004-09-30 Hanmi Pharm. Co. Ltd. Conjugue de facteur stimulant les colonies de granulocytes humain presentant une stabilite accrue dans le sang et son procede de preparation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011953A1 (fr) * 1994-10-12 1996-04-25 Amgen Inc. Compositions de proteines ayant subi une modification chimique a l'extremite n-terminale et procedes
WO1998025965A2 (fr) * 1996-12-11 1998-06-18 Glaxo Group Limited Peptides et composes qui se lient a un recepteur
WO2000021574A2 (fr) * 1998-10-14 2000-04-20 Amgen Inc. Double polyethyleneglycolation de proteines dirigee sur site pour augmenter la bioactivite et la biocompatibilite
WO2001051510A2 (fr) * 2000-01-10 2001-07-19 Maxygen Holdings Ltd Produits conjugues g-csf
WO2001076640A2 (fr) * 2000-04-07 2001-10-18 Amgen Inc. Nouvelles compositions chimiquement modifiees de proteines stimulant erythropoietine et procedes
US20030143596A1 (en) * 2001-11-07 2003-07-31 Shearwater Corporation Branched polymers and their conjugates
WO2004028568A1 (fr) * 2002-09-27 2004-04-08 F. Hoffmann-La Roche Ag Conjugues de proteine de liaison du facteur de croissance insulinomimetique 4 et de poly (ethylene glycol)
WO2004083242A1 (fr) * 2003-03-21 2004-09-30 Hanmi Pharm. Co. Ltd. Conjugue de facteur stimulant les colonies de granulocytes humain presentant une stabilite accrue dans le sang et son procede de preparation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BAILON P ET AL: "Polyethylene glycol-conjugated pharmaceutical proteins", PHARMACEUTICAL SCIENCE AND TECHNOLOGY TODAY 1998 UNITED KINGDOM, vol. 1, no. 8, 1998, pages 352 - 356, XP002354431, ISSN: 1461-5347 *
CHAMOW S M ET AL: "MODIFICATION OF CD4 IMMUNOADHESIN WITH MONOMETHOXYPOLY(ETHYLENE GLYCOL) ALDEHYDE VIA REDUCTIVE ALKYLATION", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 5, no. 2, 1 March 1994 (1994-03-01), pages 133 - 140, XP000434384, ISSN: 1043-1802 *
GRACE MICHAEL J ET AL: "Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, no. 8, 25 February 2005 (2005-02-25), pages 6327 - 6336, XP002391026, ISSN: 0021-9258 *
LEE K C ET AL: "Preparation and characterization of polyethylene-glycol-modified salmon calcitonins.", PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY. MAY 1999, vol. 4, no. 2, May 1999 (1999-05-01), pages 269 - 275, XP009069735, ISSN: 1083-7450 *
ROBERTS M J ET AL: "Chemistry for peptide and protein PEGylation", ADVANCED DRUG DELIVERY REVIEWS, AMSTERDAM, NL, vol. 54, no. 4, 17 June 2002 (2002-06-17), pages 459 - 476, XP002293146, ISSN: 0169-409X *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11559567B2 (en) 2014-11-06 2023-01-24 Pharmaessentia Corporation Dosage regimen for pegylated interferon

Also Published As

Publication number Publication date
WO2006095029A2 (fr) 2006-09-14
WO2006094530A1 (fr) 2006-09-14
JP2008535793A (ja) 2008-09-04

Similar Documents

Publication Publication Date Title
WO2006095029A3 (fr) Conjugues di-polymere-proteine et procedes de preparation de ceux-ci
WO2008006535A3 (fr) Utilisation d'une préparation colloïdale cationique pour le diagnostic et le traitement de maladies oculaires
WO2006096439A3 (fr) Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees
WO2007038459A3 (fr) Composes de carboxyamine et leurs methodes d'utilisation
WO2006096434A3 (fr) Compositions pharmaceutiques permettant de traiter et/ou de prevenir les troubles de l'anxiete
EP2450360A3 (fr) (S)-N-Méthylnaltrexone
EP2526933A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
WO2007128802A3 (fr) Utilisation de flibansérine pour le traitement des troubles de la libido post-ménopausiques
WO2006124748A3 (fr) Composes polycycliques et procedes pour les utiliser
WO2011157741A3 (fr) Conjugués anticorps humain-médicament contre le facteur tissulaire
WO2005115421A8 (fr) Utilisation d’une composition comprenant du d-mannoheptulose et/ou du perseitol dans le traitement et la prevention des maladies liees a une modification de l’immunite innee
EP2213684A3 (fr) Anticorps nogo-a pour le traitement de la maladie d'Alzheimer
WO2010069532A8 (fr) Anticorps dirigés contre l'angiopoïétine 2 humaine
WO2006058868A3 (fr) Pteridines substituees destinees au traitement de maladies inflammatoires
EP3381445A3 (fr) Formulation aqueuse d'anticorps stabilisée par des antioxydants pour administration parentérale
WO2009071690A3 (fr) Dérivés d'oxindole à double substitution en positions 5 et 6 et leur utilisation pour traiter des maladies liées à la vasopressine
WO2008076954A3 (fr) Composés hétérocycliques et procédés d'utilisation de ceux-ci
WO2009071689A3 (fr) Dérivés d'oxindole substitués par halogène en position 5 et leur utilisation pour traiter des maladies liées à la vasopressine
WO2010058926A3 (fr) Composition pharmaceutique contenant un extrait de gingembre ou du shogaol
WO2009059755A3 (fr) Nouveaux conjugués de neurturine pour une utilisation pharmaceutique
WO2007050793A3 (fr) Methodes et compositions de traitement du syndrome de marfan et de troubles associes
WO2005107810A3 (fr) Formulations pharmaceutiques et leurs utilisations dans le traitement du dysfonctionnement sexuel chez la femme
IL187575A (en) Benzofuranyl derivatives ,pharmaceutical formulations comprising the same and use thereof in the preparation of medicaments for the treatment of 5-ht6-receptor related disorders
WO2007104768A3 (fr) Conjugués de protéines di-polymères et leurs procédés d'élaboration
WO2007144422A3 (fr) Préparations combinées contenant du bifeprunox et de la l-dopa

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008500216

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 2006725029

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2006725029

Country of ref document: EP